UNDIFFERENTIATED PLEOMORPHIC SARCOMA (UPS)
Clinical trials for UNDIFFERENTIATED PLEOMORPHIC SARCOMA (UPS) explained in plain language.
Never miss a new study
Get alerted when new UNDIFFERENTIATED PLEOMORPHIC SARCOMA (UPS) trials appear
Sign up with your email to follow new studies for UNDIFFERENTIATED PLEOMORPHIC SARCOMA (UPS), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New Triple-Action pill enters human testing in fight against tough cancers
Disease control Recruiting nowThis is a first-in-human study to test the safety and find the right dose of a new oral drug, OKN4395, for people with advanced solid tumors. The trial will give the drug alone and combined with an existing immunotherapy (pembrolizumab) to about 166 participants with cancers like…
Matched conditions: UNDIFFERENTIATED PLEOMORPHIC SARCOMA (UPS)
Phase: PHASE1 • Sponsor: Epkin • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
Personalized radiation aims to spare sarcoma patients from Long-Term side effects
Disease control Recruiting nowThis study is testing whether selecting certain patients to receive proton radiation instead of standard X-ray radiation before sarcoma surgery can reduce long-term side effects while maintaining the same treatment effectiveness. For each of the 110 adult participants in Norway, …
Matched conditions: UNDIFFERENTIATED PLEOMORPHIC SARCOMA (UPS)
Phase: PHASE2 • Sponsor: Oslo University Hospital • Aim: Disease control
Last updated Mar 30, 2026 14:27 UTC
-
Proton beam trial aims to zap inoperable tumors with higher, safer doses
Disease control Recruiting nowThis study is testing whether a newer type of radiation therapy, called proton beam therapy, can be given at a higher dose to better control inoperable soft tissue sarcomas. The goal is to see if this approach stops tumor growth for at least two years without increasing side effe…
Matched conditions: UNDIFFERENTIATED PLEOMORPHIC SARCOMA (UPS)
Phase: PHASE2 • Sponsor: Oslo University Hospital • Aim: Disease control
Last updated Mar 17, 2026 13:09 UTC